Otonomy reports positive results with hearing loss candidate

A former Novo Ventures-owned biotech firm, Otonomy, has announced that a full phase II trial of its hearing loss drug candidate will take place this year after having just publicized positive results from a preceding phase IIa study.

Photo: Emrah Gurel/AP/Ritzau Scanpix

Biotech firm Otonomy, listed in the US, has scored its first top-line results from clinical studies of the candidate OTO-413, a potential hearing loss treatment, the company reports in a press release.

In a phase IIa trial that included 30 participants with hearing loss, 20 people received an injection delivering the drug into the inner ear, while the remaining patients received a placebo. Multiple speech-in-noise (SiN) tests were conducted with the participants on day 57 and 85, which included a words-in-noise test where subjects have to distinguish words from background noise, a real-life challenge for those with hearing loss, Otonomy says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs